I often use the word "if" in investments. We can't see the future. But on the balance of probablilties, I doubt the FDA will grant approval to Mesoblast for Remestemcel without better quality evidence from a much more robust and scientific randomised, controlled clinical trial.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.87 |
Change
0.070(3.90%) |
Mkt cap ! $2.405B | |||
| Open | High | Low | Value | Volume |
| $1.83 | $1.89 | $1.83 | $4.497M | 2.420M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 21 | 8267 | $1.87 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.87 | 15346 | 12 |
View Market Depth
| Last trade - 11.59am 16/06/2025 (20 minute delay) ? |
| MSB (ASX) Chart |